Blinatumomab in induction therapy improves molecular response
in untreated adults with Ph- B-cell precursor acute
lymphoblastic leukemia

CSLog in Log in (EduId)

Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell ...

Přehled o publikaci

J 2025

Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

SALEK, Cyril; Štěpán HRABOVSKÝ; František FOLBER; Zdenek KORISTEK; Jan M HORACEK et. al.

Basic information

Original name

Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Authors

Edition

haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2025, 0390-6078

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

Italy

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Lékařská fakulta – Repository – Repository

DOI

https://doi.org/10.3324/haematol.2024.287062

UT WoS

001524687800023

EID Scopus

2-s2.0-105009547616

Keywords in English

Blinatumomab; acute lymphoblastic leukemia; Ph- B-cell precursor

Links

LX22NPO5102, research and development project. NU22-03-00210, research and development project. CZECRIN IV, large research infrastructures.

Changed: 15/10/2025 00:51, RNDr. Daniel Jakubík

Abstract

In the original language

lt;10-. Patients treated in their first complete remission (CR) showed better outcomes than those treated in later remissions. These findings support integrating blinatumomab into first-line polychemotherapy, as early MRD clearance significantly improves survival and reduces risk of relapse.

Files attached

https://is.muni.cz/publication/2511397/Blinatumomab_in_induction_therapy_improves_molecular_response_in_untreated_adults_with_Ph-_B-cell_precursor_acute_lymphoblastic_leukemia.pdf

Cite

SALEK, Cyril; Štěpán HRABOVSKÝ; František FOLBER; Zdenek KORISTEK; Jan M HORACEK; Eva FRONKOVA; Leona Rezkova REZNICKOVA; Pavla PECHERKOVA; Petr SOUKUP; Barbora DLUHOSOVA; Vaclava POLIVKOVA; Jitka KRIZKOVA; Katerina MACHOVA POLAKOVA; Zuzana VRZALOVÁ; Hana HALÁMOVA; Jan TRKA; Petr CETKOVSKY and Michael DOUBEK. Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2025, vol. 110, No 7, p. 1644-1648. ISSN 0390-6078. Available from: https://doi.org/10.3324/haematol.2024.287062.

@article{80287,
   author = {Salek, Cyril and Hrabovský, Štěpán and Folber, František and Koristek, Zdenek and Horacek, Jan M and Fronkova, Eva and Reznickova, Leona Rezkova and Pecherkova, Pavla and Soukup, Petr and Dluhosova, Barbora and Polivkova, Vaclava and Krizkova, Jitka and Machova Polakova, Katerina and Vrzalová, Zuzana and Halámova, Hana and Trka, Jan and Cetkovsky, Petr and Doubek, Michael},
   article_location = {PAVIA},
   article_number = {7},
   doi = {https://doi.org/10.3324/haematol.2024.287062},
   keywords = {Blinatumomab; acute lymphoblastic leukemia; Ph- B-cell precursor},
   language = {eng},
   issn = {0390-6078},
   journal = {haematologica},
   title = {Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia},
   url = {https://haematologica.org/article/view/11946},
   volume = {110},
   year = {2025}
}

TY  - JOUR
ID  - 80287
AU  - Salek, Cyril - Hrabovský, Štěpán - Folber, František - Koristek, Zdenek - Horacek, Jan M - Fronkova, Eva - Reznickova, Leona Rezkova - Pecherkova, Pavla - Soukup, Petr - Dluhosova, Barbora - Polivkova, Vaclava - Krizkova, Jitka - Machova Polakova, Katerina - Vrzalová, Zuzana - Halámova, Hana - Trka, Jan - Cetkovsky, Petr - Doubek, Michael
PY  - 2025
TI  - Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia
JF  - haematologica
VL  - 110
IS  - 7
SP  - 1644-1648
EP  - 1644-1648
PB  - FERRATA STORTI FOUNDATION
SN  - 0390-6078
KW  - Blinatumomab
KW  - acute lymphoblastic leukemia
KW  - Ph- B-cell precursor
UR  - https://haematologica.org/article/view/11946
N2  - lt;10-. Patients treated in their first complete remission (CR) showed better outcomes than those treated in later remissions. These findings support integrating blinatumomab into first-line polychemotherapy, as early MRD clearance significantly improves survival and reduces risk of relapse.
ER  -

SALEK, Cyril; Štěpán HRABOVSKÝ; František FOLBER; Zdenek KORISTEK; Jan M HORACEK; Eva FRONKOVA; Leona Rezkova REZNICKOVA; Pavla PECHERKOVA; Petr SOUKUP; Barbora DLUHOSOVA; Vaclava POLIVKOVA; Jitka KRIZKOVA; Katerina MACHOVA POLAKOVA; Zuzana VRZALOVÁ; Hana HALÁMOVA; Jan TRKA; Petr CETKOVSKY and Michael DOUBEK. Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia. \textit{haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2025, vol.~110, No~7, p.~1644-1648. ISSN~0390-6078. Available from: https://doi.org/10.3324/haematol.2024.287062.